){kind=logo}
The GLP-1 Dividend: A New Pathway to Recurring Revenue
Today's aesthetics patient no longer fits a standard treatment pathway. With accelerating GLP-1 use and evolving patient needs, rethink how treatments are introduced, combined, and priced to build proven personalized protocols - turning new demographic demand into repeatable revenue without allowing complexity to dilute your margins.